Naltrexone SR and Fluoxetine Combination Therapy in Subjects With OCD
Understand this study
Who could participate?
This study is for people with OCD. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.
- Listed locations
- National City and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 8
- Sponsor
- Orexigen Therapeutics, Inc
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00758966
- Official title
Show the full official title
A Proof-of-Concept, Multicenter, Randomized, Double-Blind, Parallel Study of Naltrexone Sustained-Release (SR) and/or Fluoxetine Therapy in the Treatment of Subjects With Obsessive-Compulsive Disorder (OCD)
Recruitment & locations
National City · San Diego · Gainesville
8 more locations
- Atlanta
- Indianapolis
- Princeton
- Brooklyn
- Cincinnati
- Portland
- Columbia
- Brown Deer
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Orexigen Therapeutics, Inc.
Does this study involve medication?
Yes. The study involves medication, including Fluoxetine 60 mg, Naltrexone 32 mg and fluoxetine 60 mg and Naltrexone SR 32 mg.
Who can participate?
This study is for people with OCD. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
